0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women:  The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

Valery T. Miller, MD; John LaRosa, MD; Vanessa Barnabei, MD, PhD; Craig Kessler, MD; Ginny Levin; Ann Smith-Roth; Margaret Griffin, RN, PA; Diane B. Stoy, RN, BS, PhD; Trudy Bush, PhD; Howard Zacur, MD, PhD; David Foster, MD; Jean Anderson, MD; Alice McKenzie, MS; Susan Miller, ScD; Peter D. Wood, DSc; Marcia L. Stefanick, PhD; Robert Marcus, MD; Allison Akana, PA; W. LeRoy Heinrichs, MD; Charlene Kirchner, RD; Katherine O'Hanlan, MD; Melissa Ruyle; Mary Sheehan, MS; Howard L. Judd, MD; Gail Greendale, MD; Richard Bayalos, MD; Kathy Lozano, RNP; Kathy Kawakami, RN; Elizabeth Barrett-Connor, MD; Robert Langer, MD; Donna Kritz-Silverstein, PhD; Mary Lou Carrion-Petersen, RN; Carmela Cavero, MS, CNM; Helmut G. Schrott, MD; Susan R. Johnson, MD; Deborah A. Feddersen, RN; Denise L. Krutzfeldt; Jo Ann Benda, MD; Carl Pauerstein, MD; Jose Trabal, MD; Robert Schenken, MD; Michael P. Stern, MD; Mercedes Rodriguez-Sifuentes, RN; Carann Easton, RN; H. Wells, PhD; Mark Espeland, PhD; George Howard, DrPh; Robert Byington, PhD; Claudine Legault, PhD; Sally Shumaker, PhD; Patricia Hogan, MS; Don Hire, BS; Carol Wasilauskas, MS; Margaret James, MS; Kathy Lane, BS; Tim Terrell, MS; Stephanie Reece, BS; June Pierce, AB; Mary Snow; Susan Anthony, BS; Irma L. Mebane-Sims, PhD; Paula Einhorn, MD; Sally Hunsberger, PhD; Myron Waclawiw, PhD; Ken Lippel, PhD; Diane Lucas, PhD; Joel Verter, PhD; Sherry Jackson, MD; Joseph Kelaghan, MD; Jeffrey Perlman, MD; Pam Wolf, PhD; Joan McGowan, PhD; Stephen Gordon, PhD; Stephen Heyse, MD; Judith Fradkin, MD; Sherry Sherman, PhD; Lot Page, MD; Ann Sorenson, PhD; Barbara Hulka, MD; Baruch Brody, PhD; Ronald Burkman, MD; Robert Heaney, MD; Ronald Krauss, MD; Harold Roberts, MD; Janet Wittes, PhD; Lawrence Riggs, MD; Richard Moss; John Albers, PhD; Santica Marcovina, PhD; S. Edwin Fineberg, PhD; Russell P. Tracy, PhD; Maria Merino, MD; Robert Scully, MD; Virginia Livolsi, MD; Gerald Kessler, PhD
JAMA. 1995;273(3):199-208. doi:10.1001/jama.1995.03520270033028.
Text Size: A A A
Published online

Objective.  —To assess pairwise differences between placebo, unopposed estrogen, and each of three estrogen/progestin regimens on selected heart disease risk factors in healthy postmenopausal women.

Design.  —A 3-year, multicenter, randomized, double-blind, placebo-controlled trial.

Participants.  —A total of 875 healthy postmenopausal women aged 45 to 64 years who had no known contraindication to hormone therapy.

Intervention.  —Participants were randomly assigned in equal numbers to the following groups: (1) placebo; (2) conjugated equine estrogen (CEE), 0.625 mg/d; (3) CEE, 0.625 mg/d plus cyclic medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo; (4) CEE, 0.625 mg/d plus consecutive MPA, 2.5 mg/d; or (5) CEE, 0.625 mg/d plus cyclic micronized progesterone (MP), 200 mg/d for 12 d/mo.

Primary Endpoints.  —Four endpoints were chosen to represent four biological systems related to the risk of cardiovascular disease: (1) high-density lipoprotein cholesterol (HDL-C), (2) systolic blood pressure, (3) serum insulin, and (4) fibrinogen.

Analysis.  —Analyses presented are by intention to treat. P values for primary endpoints are adjusted for multiple comparisons; 95% confidence intervals around estimated effects were calculated without this adjustment.

Results.  —Mean changes in HDL-C segregated treatment regimens into three statistically distinct groups: (1) placebo (decrease of 0.03 mmol/L [1.2 mg/dL]); (2) MPA regimens (increases of 0.03 to 0.04 mmol/L [1.2 to 1.6 mg/dL]); and (3) CEE with cyclic MP (increase of 0.11 mmol/L [4.1 mg/dL]) and CEE alone (increase of 0.14 mmol/L [5.6 mg/dL]). Active treatments decreased mean low-density lipoprotein cholesterol (0.37 to 0.46 mmol/L [14.5 to 17.7 mg/dL]) and increased mean triglyceride (0.13 to 0.15 mmol/L [11.4 to 13.7 mg/dL]) compared with placebo. Placebo was associated with a significantly greater increase in mean fibrinogen than any active treatment (0.10 g/L compared with -0.02 to 0.06 g/L); differences among active treatments were not significant. Systolic blood pressure increased and postchallenge insulin levels decreased during the trial, but neither varied significantly by treatment assignment. Compared with other active treatments, unopposed estrogen was associated with a significantly increased risk of adenomatous or atypical hyperplasia (34% vs 1%) and of hysterectomy (6% vs 1%). No other adverse effect differed by treatment assignment or hysterectomy status.

Conclusions.  —Estrogen alone or in combination with a progestin improves lipoproteins and lowers fibrinogen levels without detectable effects on postchallenge insulin or blood pressure. Unopposed estrogen is the optimal regimen for elevation of HDL-C, but the high rate of endometrial hyperplasia restricts use to women without a uterus. In women with a uterus, CEE with cyclic MP has the most favorable effect on HDL-C and no excess risk of endometrial hyperplasia.(JAMA. 1995;273:199-208)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();